Synthesis and Development of Indole Based 5-HT3 Receptor Antagonists as Anti-Emetic Drugs in Oncology: An Update

Title:Synthesis and Development of Indole Based 5-HT3 Receptor Antagonists as Anti-Emetic Drugs in Oncology: An Update

Volume: 28 Issue: 42

Author(s): Johana L. Rivera-Fonseca, Nelly González-Rivas, M. V. Basavanag Unnamatla, Marco A. García-Eleno, Horacio Reyes, L. Germán López-Valdez, David Corona-Becerril and Erick Cuevas-Yañez*

Affiliation:

• Centro Conjunto de Investigación en Química Sustentable UAEM-UNAM, Carretera Toluca-Atlacomulco Km. 14.5, Toluca, Estado de México 50200, Mexico
• Facultad de Química, Universidad Autónoma del Estado de México. Paseo Colón esq. Paseo Tollocan, 50120, Toluca, Mexico

Keywords: Antiemetic drugs, 5-HT3, indole, synthesis, ondansetron, ramosetron, dolasetron, granisetron, ricasetron, tropisetron.

Abstract: An important group of antiemetic drugs used in the treatment of nausea and vomiting after chemotherapy containing an indole moiety in their structures, working as 5- hydroxytryptamine type 3 serotonin receptor antagonist (5-HT3). This study focuses on compounds bearing an indole core that present a 5-HT3 receptor antagonist activity, which have been successfully used as antiemetic drugs for reducing chemotherapy adverse secondary effects during cancer treatment. Their synthesis, biological activities, and some outstanding characteristics are discussed, providing a general outlook towards the development of more efficient antiemetic drugs.

Cite this article as:

Rivera-Fonseca L. Johana , González-Rivas Nelly , Unnamatla Basavanag M. V. , García-Eleno A. Marco , Reyes Horacio , López-Valdez Germán L. , Corona-Becerril David and Cuevas-Yañez Erick *, Synthesis and Development of Indole Based 5-HT3 Receptor Antagonists as Anti-Emetic Drugs in Oncology: An Update, Current Medicinal Chemistry 2021; 28 (42) . https://dx.doi.org/10.2174/0929867328666210708091134